• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

男性性腺功能减退症:发病机制、诊断与治疗。

Male hypogonadism: pathogenesis, diagnosis, and management.

机构信息

Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK; Faculty of Medicine, General Sir John Kotelawala Defence University, Colombo, Sri Lanka.

Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.

出版信息

Lancet Diabetes Endocrinol. 2024 Oct;12(10):761-774. doi: 10.1016/S2213-8587(24)00199-2. Epub 2024 Aug 16.

DOI:10.1016/S2213-8587(24)00199-2
Abstract

Organic male hypogonadism due to irreversible hypothalamic-pituitary-testicular (HPT) pathology is easily diagnosed and treated with testosterone-replacement therapy. However, controversy surrounds the global practice of prescribing testosterone to symptomatic men with low testosterone and non-gonadal factors reducing health status, such as obesity, type 2 diabetes, and ageing (ie, functional hypogonadism), but without identifiable HPT axis pathology. Health optimisation remains the gold-standard management strategy. Nevertheless, in the last decade large clinical trials and an individual patient data meta-analysis of smaller clinical trials confirmed that testosterone therapy induces modest, yet statistically significant, improvements in sexual function without increasing short-term to medium-term cardiovascular or prostate cancer risks in men with functional hypogonadism. Although testosterone improves bone mineral density and insulin sensitivity in these men, trials from the last decade suggest insufficient evidence to determine the safety and effectiveness of use of this hormone for the prevention of fractures or type 2 diabetes. This Review discusses the pathogenesis and diagnosis of male hypogonadism and appraises the evidence underpinning the management of this condition.

摘要

由于下丘脑-垂体-睾丸(HPT)轴不可逆的病理变化导致的男性性腺功能减退症很容易被诊断和治疗,通过补充睾酮即可。然而,目前对于因非性腺因素导致健康状况下降(如肥胖、2 型糖尿病和衰老,即功能性性腺功能减退症)而出现低睾酮症状的男性,全球范围内应用睾酮治疗存在争议,这些患者并没有明确的 HPT 轴病理变化。健康优化仍然是黄金标准的管理策略。然而,在过去的十年中,大型临床试验和对较小临床试验的个体患者数据进行的荟萃分析证实,睾酮治疗可适度但具有统计学意义地改善性功能,而不会增加功能性性腺功能减退症男性的短期至中期心血管或前列腺癌风险。尽管睾酮可改善这些男性的骨密度和胰岛素敏感性,但过去十年的试验表明,尚无足够的证据确定该激素用于预防骨折或 2 型糖尿病的安全性和有效性。这篇综述讨论了男性性腺功能减退症的发病机制和诊断,并评估了支持这种治疗方法的证据。

相似文献

1
Male hypogonadism: pathogenesis, diagnosis, and management.男性性腺功能减退症:发病机制、诊断与治疗。
Lancet Diabetes Endocrinol. 2024 Oct;12(10):761-774. doi: 10.1016/S2213-8587(24)00199-2. Epub 2024 Aug 16.
2
The effects and safety of testosterone replacement therapy for men with hypogonadism: the TestES evidence synthesis and economic evaluation.男性性腺功能减退症患者睾酮替代治疗的效果和安全性:TestES 证据综合和经济评估。
Health Technol Assess. 2024 Aug;28(43):1-210. doi: 10.3310/JRYT3981.
3
Testosterone therapy in older men: clinical implications of recent landmark trials.老年男性睾酮治疗:近期里程碑式试验的临床意义。
Eur J Endocrinol. 2024 Jul 2;191(1):R22-R31. doi: 10.1093/ejendo/lvae071.
4
Beyond T-Trials, T4DM and TRAVERSE: the next large testosterone randomized controlled trial.超越 T 试验、T4DM 和 TRAVERSE:下一个大型睾酮随机对照试验。
Curr Opin Endocrinol Diabetes Obes. 2024 Dec 1;31(6):222-229. doi: 10.1097/MED.0000000000000886. Epub 2024 Sep 18.
5
Indications for testosterone therapy in men.男性睾酮治疗的适应证。
Curr Opin Endocrinol Diabetes Obes. 2024 Dec 1;31(6):249-256. doi: 10.1097/MED.0000000000000890.
6
Testosterone therapy for functional hypogonadism in middle-aged and elderly males: current evidence and future perspectives.中老年男性功能性性腺功能减退症的睾酮治疗:当前证据与未来展望。
Hormones (Athens). 2024 Dec;23(4):801-817. doi: 10.1007/s42000-024-00587-2. Epub 2024 Jul 26.
7
Current National and International Guidelines for the Management of Male Hypogonadism: Helping Clinicians to Navigate Variation in Diagnostic Criteria and Treatment Recommendations.当前男性性腺功能减退症管理的国家和国际指南:帮助临床医生应对诊断标准和治疗建议的差异。
Endocrinol Metab (Seoul). 2020 Sep;35(3):526-540. doi: 10.3803/EnM.2020.760. Epub 2020 Sep 22.
8
EMAS position statement: Testosterone replacement therapy in older men.欧洲老化医学学会立场声明:老年男性的睾丸素替代疗法。
Maturitas. 2023 Dec;178:107854. doi: 10.1016/j.maturitas.2023.107854. Epub 2023 Oct 15.
9
Late-onset hypogonadism: metabolic impact.迟发性性腺功能减退症:代谢影响。
Andrology. 2020 Nov;8(6):1519-1529. doi: 10.1111/andr.12705. Epub 2019 Sep 25.
10
Hypothalamic-pituitary-gonadal axis and sexual functioning in metformin-treated men after discontinuation of testosterone replacement therapy: A pilot study.二甲双胍治疗男性停用睾酮替代治疗后下丘脑-垂体-性腺轴和性功能的变化:一项初步研究。
J Clin Pharm Ther. 2021 Dec;46(6):1764-1775. doi: 10.1111/jcpt.13528. Epub 2021 Sep 6.

引用本文的文献

1
Therapeutic effects of a pulsatile GnRH pump on adult male patients with congenital hypogonadotropic hypogonadism (CHH): a retrospective study.脉冲式GnRH泵对成年先天性低促性腺激素性性腺功能减退(CHH)男性患者的治疗效果:一项回顾性研究。
Transl Androl Urol. 2025 Jul 30;14(7):2043-2058. doi: 10.21037/tau-2025-199. Epub 2025 Jul 28.
2
Testosterone-induced erythrocytosis: addressing the challenge of metabolic syndrome and widely prescribed SGLT2-inhibitor drugs.睾酮诱导的红细胞增多症:应对代谢综合征和广泛使用的SGLT2抑制剂药物带来的挑战。
Endocr Connect. 2025 Jun 21;14(6). doi: 10.1530/EC-24-0695. Print 2025 Jun 1.
3
Unlocking the power of semen analysis in primary health care - a path to men's health and lifestyle transformation.
释放初级卫生保健中精液分析的力量——通往男性健康与生活方式转变之路。
Nat Rev Urol. 2025 Jun 6. doi: 10.1038/s41585-025-01047-1.
4
Testosterone Therapy in Older Men: Present and Future Considerations.老年男性的睾酮治疗:现状与未来考量
Drugs Aging. 2025 Apr 27. doi: 10.1007/s40266-025-01209-1.
5
An Update on Advances in Hypopituitarism: Etiology, Diagnosis, and Current Management.垂体功能减退症的进展更新:病因、诊断及当前治疗
J Clin Med. 2024 Oct 16;13(20):6161. doi: 10.3390/jcm13206161.